Stock-Based Compensation - (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands								3 Months Ended	9 Months Ended		12 Months Ended
		Mar. 04, 2021	Mar. 01, 2021	May 01, 2020	May 01, 2020	Mar. 12, 2020	Mar. 15, 2019	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Proceeds from issuance of common stock											$ 16,032	$ 5,413
Lucid Diagnostics Inc [Member] | Research and Development Expenses [Member]
Stock-based compensation expense											65	174
Restricted Stock [Member] | General and Administrative Expenses [Member]
Stock-based compensation expense											$ 576	$ 206
Employee Stock Purchase Plan [Member]
Stock options available-for-grant											360,673
Vesting portion of stock											ESPP share purchase dates are March 31 and September 30. On each of the March 31, 2020 and September 30, 2020 ESPP purchase dates, 154,266 and 152,289 shares of PAVmed Inc. common stock were issued for proceeds of approximately $126 and $231, respectively; and in the previous year, on the initial September 30, 2019 ESPP purchase date, 82,772 shares of PAVmed Inc. common stock were issued for proceeds of approximately $67.
Proceeds from issuance of common stock								$ 126	$ 231	$ 67
Purchase price per share percentage on ESPP plan											85.00%
Number of stock purchase of common stock								154,266	152,289	82,772
Number of common stock reserved											750,000
Board of Directors [Member] | Employee Stock Purchase Plan [Member] | Maximum [Member]
Increase in stock options available-for-grant						500,000
2014 Equity Plan [Member]
Stock options available-for-grant											2,003,406
Weighted average exercise price per shares	[1]										$ 2.13	$ 1.00
Stock option granted, contractual term											10 years
Weighted average fair value of stock options											$ 1.27	0.48
Contractual term											5 years 9 months 18 days
Expected stock price volatility											73.00%
Risk free interest rate											0.50%
Expected dividend rate											0.00%
2014 Equity Plan [Member] | Subsequent Event [Member]
Stock options grant		225,000
Weighted average exercise price per shares		$ 2.03
2014 Equity Plan [Member] | Available-for-Grant [Member]
Stock options grant											500,854
2014 Equity Plan [Member] | Restricted Stock [Member]
Number of restricted stock award granted				950,000	950,000		700,000
Vesting portion of stock					2014 Equity Plan, vesting as follows: 450,000 restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021		2014 Equity Plan, vesting as follows: 233,334 restricted stock awards vested on March 15, 2020; and 466,666 restricted awards vesting on March 15, 2022.
Restricted stock awards vested					450,000		233,334
Stock-based compensation expense				$ 1,938			$ 742
2014 Equity Plan [Member] | Restricted Stock [Member] | May 1, 2023 [Member]
Restricted stock awards vested					500,000
2014 Equity Plan [Member] | Restricted Stock [Member] | March 15, 2022 [Member]
Restricted stock awards vested							466,666
2014 Equity Plan [Member] | Board of Directors [Member]
Increase in stock options available-for-grant						2,000,000
2014 Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options												$ 1.97
Contractual term												8 years 6 months
Expected stock price volatility												59.00%
Risk free interest rate												2.30%
Expected dividend rate												0.00%
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Stock options available-for-grant											1,305,000
Stock options grant
Stock issued during the period											2,000,000
2018 Equity Plan [Member] | Subsequent Event [Member] | Lucid Diagnostics Inc [Member]
Restricted stock awards vested			1,040,000
2018 Equity Plan [Member] | Stock Option [Member] | Lucid Diagnostics Inc [Member]
Stock options grant											300,000
2018 Stock Plan [Member]
Weighted average exercise price per shares												$ 1.02
Number of common stock issued											3,333
Proceeds from issuance of common stock											$ 5
2018 Long-Term Incentive Equity Plan [Member]
Weighted average fair value of stock options											$ 0.32
2018 Long-Term Incentive Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options												$ 0.29
Contractual term												8 years 9 months 18 days
Expected stock price volatility												57.00%
Risk free interest rate												2.10%
Expected dividend rate												0.00%

[1] Stock options granted under the PAVmed Inc. 2014 Equity Plan vest ratably over twelve quarters generally commencing with the grant date quarter and have a ten year contractual term from date-of-grant.